Browse > Article

Pharmacokinetic Properties and Bioequivalence of Cefcapene Pivoxil Hydrochloride 75 mg in Korean Healthy Volunteers  

Jeon, Ji-Young (Clinical Trial Center, Chonbuk National University Hospital)
Im, Yong-Jin (Clinical Trial Center, Chonbuk National University Hospital)
Hwang, Min-Ho (Clinical Trial Center, Chonbuk National University Hospital)
Kim, Yun-Jeong (Clinical Trial Center, Chonbuk National University Hospital)
Han, Su-Mi (Clinical Trial Center, Chonbuk National University Hospital)
Jo, Myeong-Jin (Clinical Trial Center, Chonbuk National University Hospital)
Kim, Hee-Sun (Daewoong Pharmaceutical Co. Ltd.)
Kim, Sun-Young (Daewoong Pharmaceutical Co. Ltd.)
Chae, Soo-Wan (Seoul Pharma Laboratories)
Kim, Kang-Seog (Clinical Trial Center, Chonbuk National University Hospital)
Kim, Min-Gul (Clinical Trial Center, Chonbuk National University Hospital)
Publication Information
Korean Journal of Clinical Pharmacy / v.22, no.1, 2012 , pp. 9-12 More about this Journal
Abstract
Background: Cefcapene pivoxil hydrochloride, is an ester-type oral cephem antibiotic. This study was performed to compare the pharmacokinetics and evaluate the bioequivalence of two cefcapene pivoxil hydrochloride 75 mg formulations. Method: In a randomized $2{\times}2$ crossover study, sixty healthy male volunteers were randomly assigned into two groups. After a single dose of 75 mg cefcapene pivoxil hydrochloride oral administration, blood samples were collected at specific time intervals from 0-12 hours. The plasma concentrations of cefcapene pivoxil hydrochloride were determined by LC-MS/MS. The pharmacokinetic parameters were determined from the plasma concentration-time profiles of both formulations. The pharmacokinetic parameters such as $AUC_{last}$, $AUC_{inf}$ and $C_{max}$, were calculated and the 90% confidence intervals for test/reference ratio for pharmacokinetic parameters were obtained by analysis of variance on logarithmically transformed data. Results: The mean value for $AUC_{last}$ in test and reference drug was $4053.1{\pm}876.5\;ng{\cdot}hr/mL$ and $3595.7{\pm}1029.1\;ng{\cdot}h/mL$, respectively. The mean value for $C_{max}$ in test and reference drug was $1324.9{\pm}321.4$ ng/mL and $1159.1{\pm}335.9$ ng/mL, respectively. The 90% confidence intervals of the $AUC_{last}$ and $C_{max}$ ratio for test drug and reference drug were log 1.09-log1.22 and log 1.09-log1.24, respectively. No adverse events were reported by subjects or found on analysis of vital signs or laboratory tests. Conclusion: This single dose study found that the test and reference products met the regulatory criteria for bioequivalence in these health volunteers. Both formulations were safe and well tolerated in 75 mg of cefcapene pivoxil hydrochloride.
Keywords
Cefcapene pivoxil hydrochloride; pharmacokinetics; bioequivalence; antibiotics;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Tanimura H, Uchiyama K, Onishi H, et al., Study of the absorption of cefcapene pivoxil in patients with infectious disease and soft stool or diarrhea. J Infect Chemother 2003; 9: 75-82.   DOI   ScienceOn
2 Sakata H. Comparative study of 5-day cefcapene-pivoxil and 10-day amoxicillin or cefcapene-pivoxil for treatment of group A streptococcal pharyngitis in children. J Infect Chemother 2008; 14: 208-12.   DOI   ScienceOn
3 Saito A, Hiraga Y, Watanabe A, et al., Comparative clinical study of cefcapene pivoxil and cefteram pivoxil in chronic respiratory tract infections by a double-blind method. J Int Med Res 2004; 32: 590-607.   DOI   ScienceOn
4 Fujimoto M. Pharmacokinetics of cefcapene pivoxil and AS-924 in gastrectomized patients. Int J Antimicrob Agents 2001;18:489-94.   DOI   ScienceOn
5 Fujii R, Abe T, Tajima T, et al., [Pharmacokinetic and clinical studies of S-1108 in the pediatric field. Pediatric Study Group of S-1108]. Jpn J Antibiot 1995; 48: 921-41.
6 Adopted by the 18th WMA General Assembly H, Finland, June 1964, and amended by the 59th WMA General Assembly, Seoul. WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects. 2008.
7 생물학적동등성시험기준. 식품의약품안전청 고시 제2010- 43호.
8 의약품동등성시험관리규정. 식품의약품안전청 고시 제 2010-44호.